Aravax
Melbourne, Australia
11 employees
Series B
Total: $42.20M
Biotechnology, Health Care +1
General Information
Melbourne, Australia
BounceWatch is an independent company data service, not affiliated with Aravax. To contact Aravax, visit aravax.com.au.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Aravax compare?
A PDF of Aravax and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Aravax soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
Australia Market
Biotechnology
About Aravax
Business keywords: clinical stage, immunotherapy, peanut allergy treatment, peptide-based therapy, immune system modulation, clinical research, startup, investor, intellectual property, food allergy, Melbourne, Australia, Alfred Health
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series B | $22.20M | 5 |
|
23 Jan 2024 |
| Series B | $20.00M | 2 |
|
20 Dec 2022 |
| Seed Round | Undisclosed | 2 |
-logo.jpg){kind=logo}
|
01 Jan 2016 |
Latest News
View All
Aravax Alternatives & Competitors
View All Alternatives
Dedicated to developing safe and effective options for peanut and other food allergies
On a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin...
Regulating Inflammation - through the nervous system
FAQ About Aravax
Source: BounceWatch company record for Aravax, https://bouncewatch.com/company/aravax, updated 9 November 2024. When citing, please name BounceWatch and link this page.
